BeOne Medicines
$358.77Change from previous close: −1.96%Absolute change: −$7.17
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $40.58B
- Enterprise value
- $37.74B
- P/E (trailing 12 months)
- 65.3
- Forward P/E
- 35.0
- PEG
- 0.77
- Price/book
- 7.84
- Price/sales
- 6.62
- EV/EBITDA
- 35.2
- EV/revenue
- 6.16
Profitability and growth
- Gross margin
- 88.9%
- Operating margin
- 19.1%
- Net margin
- 10.7%
- ROE
- 14.7%
- ROA
- 7.5%
- Revenue growth (year over year)
- 29.6%
- Earnings growth (year over year)
- 166.7%
Financial health
- Total cash
- $5.1B
- Total debt
- $2.05B
- Debt/equity
- 0.40
- Current ratio
- 3.41
- Quick ratio
- 2.91
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $433.52
- Median price target
- $434.71
- High price target
- $528.00
- Low price target
- $370.00
- Analysts with a price target
- 28
- Consensus
- Strong buy
- Forward EPS
- $10.25
- EPS estimate, current year
- $7.62
Shares and trading
- Beta
- 0.52
- Average volume
- 388.77K
- Shares outstanding
- 104.27M
- Float
- 80.96M
- Institutional ownership
- 33.2%
- Insider ownership
- 17.3%
- Short interest (% of float)
- 2.1%
- Short ratio (days)
- 4.67